LivaNova Valuation Multiples

LivaNova Overview

About LivaNova

UK-based LivaNova was born of a combination of Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.

Founded

2015

HQ

Employees

2.9K

Website

livanova.com

Sectors

Medical DevicesDeepTechHealthTech

Financials (LTM)

Revenue: $1B

EBITDA: $322M

EV

$3B

Valuation Multiples

Multiples.vc

Start free trial

LivaNova Financials

LivaNova reported last 12-month revenue of $1B and EBITDA of $322M.

In the same LTM period, LivaNova generated $971M in gross profit, $322M in EBITDA, and $221M in net income.

LivaNova P&L

In the most recent fiscal year, LivaNova reported revenue of $1B and EBITDA of $317M.

LivaNova expects next 12-month revenue of XXX and NTM EBITDA of XXX

LivaNova Stock Performance

LivaNova has current market cap of $4B, and enterprise value of $3B.

LivaNova's stock price is $67.08.

LivaNova Valuation Multiples

LivaNova trades at 2.4x EV/Revenue multiple, and 10.8x EV/EBITDA.

LivaNova Financial Valuation Multiples

As of April 20, 2026, LivaNova has market cap of $4B and EV of $3B.

Equity research analysts estimate LivaNova's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

LivaNova has a P/E ratio of 16.6x.

LivaNova Margins & Growth Rates

LivaNova's revenue in the last 12 month grew by 7%.

LivaNova's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.3M for the same period.

LivaNova's rule of 40 is 30% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

LivaNova's rule of X is 42% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

LivaNova Public Comps

See public comps and valuation multiples for other Medical Devices comps.

LivaNova M&A Activity

LivaNova acquired XXX companies to date.

Last acquisition by LivaNova was on XXXXXXXX, XXXXX. LivaNova acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

LivaNova Investment Activity

LivaNova invested in XXX companies to date.

LivaNova made its latest investment on XXXXXXXX, XXXXX. LivaNova invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).